HSBC Holdings
CLDX icon

HSBC Holdings’s Celldex Therapeutics CLDX Stock Holding History

HSBC Holdings’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,145
Closed -$211K – 2968
2025
Q3 		$211K Sell
8,145
-9,434
-54% -$219K ﹤0.01% 2471
2025
Q2 		$347K Buy
+17,579
New +$342K ﹤0.01% 2353
2025
Q1 		– Sell
-9,292
Closed -$233K – 3074
2024
Q4 		$233K Buy
+9,292
New +$252K ﹤0.01% 2632
2017
Q1 		– Sell
-1,097
Closed -$58K – 2189
2016
Q4 		$58K Buy
+1,097
New +$62.4K ﹤0.01% 2659

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

HSBC Holdings's CLDX Position: Q4 2025 in Review

HSBC Holdings sold out of Celldex Therapeutics (CLDX) in Q4 2025, closing a stake of 8,145 shares — an estimated $211K sold.

HSBC Holdings first reported a position in CLDX in Q4 2016 and held it in 4 quarters. The position peaked at $347K in Q2 2025. 185 funds tracked by Wall St. Rank hold CLDX as of Q4 2025.

  • HSBC Holdings reported no remaining Celldex Therapeutics position as of Q4 2025 after selling out during the quarter.
  • HSBC Holdings sold 8,145 Celldex Therapeutics shares in Q4 2025, an estimated $211K.
  • HSBC Holdings first reported a position in Celldex Therapeutics in Q4 2016 and held it in 4 quarters.
  • HSBC Holdings's Celldex Therapeutics position peaked at $347K in Q2 2025.
  • 185 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2025.

Based on HSBC Holdings's 13F filing for Q4 2025, filed 6 Mar 2026.